The size of the Europe Plasma Fractionation Market was worth USD 6.15 billion in 2021. It is projected to be growing at a CAGR of 6.10% to touch USD 8.27 billion by 2026.
Plasma Fractionation consists of a screening ad fractionating procedure in which the blood is split into its constituents of the plasma and RBCs, WBCs, and platelets. The plasma is studied for various deficiencies and replaced, or treatment is prescribed.
Plasma is a necessary constituent of blood as it constitutes about 55% blood by volume and carries more than a thousand proteins and other substances like electrolytes. These hormones are required for the optimal function of the human body. Albumin is one of the significant proteins which is replaced and also used to compensate during plasma exchange.
The growth of the Europe Plasma Fractionation Market is mainly driven by factors such as the increasing incidence of immune and bleeding disorders, the growing incidence of Alpha-1 Antitrypsin deficiency, and the rising use of immunoglobulins. Further, an increasingly aging population with related blood-related ailments is set to promote market growth. However, adverse reactions associated with the use of plasma fractionation and transfer, high costs of plasma products, and unfavorable reimbursement policies are the significant constraints of market growth.
This research report on Europe Plasma Fractionation Market has been segmented and sub-segmented into the following categories:
Some of the Top Companies leading the Europe Plasma Fractionation Market Profiled in the Report are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Fractionation Process
5.1.3 Immunoglobulin
5.1.4 Coagulation Factor Concentrates
5.1.5 Albumin
5.1.6 Protease Inhibitors
5.1.7 Y-o-Y Growth Analysis, By Product
5.1.8 Market Attractiveness Analysis, By Product
5.1.9 Market Share Analysis, By Product
5.2 Application
5.2.1 Introduction
5.2.2 Neurology
5.2.3 Immunology
5.2.4 Hematology
5.2.5 Critical Care
5.2.6 Pulmonology
5.2.7 Hemato-Oncology
5.2.8 Rheumatology
5.2.9 Other Application
5.2.10 Y-o-Y Growth Analysis, By Application
5.2.11 Market Attractiveness Analysis, By Application
5.2.12 Market Share Analysis, By Application
5.3 End User
5.4.1 Introduction
5.4.2 Hospitals
5.4.3 Clinical Laboratories
5.4.4 Academic Institutes
5.4.5 Y-o-Y Growth Analysis, By End User
5.4.6 Market Attractiveness Analysis, By End User
5.4.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Application
6.1.3.4 By Indication
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Application
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Application
6.1.5.4 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Baxalta Incorporated
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 CSL Ltd.
8.3 Grifols S.A
8.4 Octapharma AG
8.5 Kedrion S.p.A
8.6 Bio Products Laboratory
8.7 Sanquin
8.8 China Biologic Products, Inc.
8.9 Biotest AG
8.10 Laboratoire Français du Fractionnement et des Biotechnologies
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
